![](https://endpts.com/wp-content/uploads/2021/02/David-Zaccardelli-Verona-Pharma-tile-scaled.jpg)
David Zaccardelli, Verona Pharma CEO
Verona inks financing deal worth up to $650M ahead of COPD decision
Verona Pharma has secured up to $650 million to aid the potential launch of its COPD candidate ensifentrine.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.